Dupixent® (dupilumab) approved by European Commission as first and only biologic medicine for children aged 6 to 11 years with severe atopic dermatitis

    NEXT STORY
    Allarity Therapeutics Publishes Interim Report for the Period January – September 2020
    PREV STORY
    EIB supports AB Science in its COVID-19 development programme
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Trodelvy™ Significantly Extends Survival in Phase 3 ASCENT Study of Metastatic Triple-Negative Breast Cancer

    author_avatar
    NASDAQ Market News

    TESARO Announces Appointment of Dr. Kavita Patel to Board of Directors

    WALTHAM, Mass., April 04, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical ...

    author_avatar
    NASDAQ Market News

    Arvinas Releases Updated Dose Escalation Data from Clinical Trial of PROTAC® Protein Degrader ARV-110 in Patients with Metastatic Castration-Resistant Prostate Cancer

    author_avatar
    NASDAQ Market News